Open for inclusion

An Open-label multicenter dose escalation phase 1 study with an expansion phase to evaluate safety pharmacokinetics and therapeutic activity of RO6895882 an immunocytokine consisting of a variant of interleukin-2 (IL-2v) targeting carcinoembryonic antigen

Cancer type: Solide tumores

Phase: I

Principal Investigator: Lassen Ulrik

Country: DK

Keywords: Denmark, Rigshospitalet, CEA, IL-2v, ADC

Status: Open for inclusion

Link to Clinicaltrials.gov: https://clinicaltrials.gov/ct2/show/NCT02004106?term=BP28920&rank=1